Business Context and Reporting Period
This Form 8-K is filed by Akers Biosciences, Inc. (Ticker: AKER) for the reporting period of May 14, 2020. The company is a biotechnology firm focused on vaccine development and screening products, currently operating under a strategic review of its screening and testing business lines.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the current period. However, it notes the following financial conditions:
- Revenue: The company reports continued low sales revenue from screening and testing products due to reduced volumes and a production backlog.
- Liquidity and Debt: No specific liquidity or debt metrics are disclosed in this report.
- Contractual Obligations: The company has an outstanding obligation under a Membership Interest Purchase Agreement (MIPA) with Cystron Biotech, LLC, involving potential equity offering payments totaling up to $11,000,000 ($1,000,000 initial + 10% of proceeds over $8,000,000).
Material Changes
- MIPA Amendment: On May 14, 2020, the company amended its March 2020 agreement with Cystron Biotech. Equity Offering Payments related to offerings consummated before September 23, 2020, are now accrued but not due until September 24, 2020.
- Operational Shift: The company has eliminated its sales force for screening and testing products and is experiencing a production backlog, leading to reduced sales volumes compared to prior years.
- Strategic Review: A strategic review of the screening and testing business has been initiated, exploring potential disposition or winddown of this segment.
Outlook, Risks, and Management Commentary
- COVID-19 Vaccine Progress: The company announced that its partner, Premas Biotech PVT Ltd., has successfully completed a vaccine prototype targeting the COVID-19 pandemic.
- Business Model Risk: The makeup of the company's lines of business is subject to change as the strategic review of the screening and testing division proceeds.
- Market Conditions: Continued reduced volumes in screening products pose a risk to near-term revenue generation from that segment.
Investor Verification Checklist
- Verify the status and timeline of the strategic review regarding the potential disposition of the screening and testing business.
- Confirm the progress of the COVID-19 vaccine candidate with partner Premas Biotech beyond the prototype stage.
- Monitor future equity offerings to determine if the $11,000,000 contingent payment obligation to Cystron Biotech will be triggered.
- Review upcoming financial statements for specific revenue and cash flow impacts resulting from the elimination of the sales force and production backlogs.